Jaiswal, Arunima
Jaiswal, Aruna
Williamson, Elizabeth A.
Gelfond, Jonathon
Zheng, Guangrong
Zhou, Daohong
Hromas, Robert http://orcid.org/0000-0002-1916-6276
Funding for this research was provided by:
Division of Cancer Epidemiology and Genetics, National Cancer Institute (CA242003, CA205224)
Cancer Prevention and Research Institute of Texas (RP220269)
Article History
Received: 8 August 2022
Accepted: 30 October 2022
First Online: 8 November 2022
Declarations
:
: G.Z. and D.Z. hold patents for use of BCL-X<sub>L</sub> PROTACs as senolytic and antitumor agents. G.Z., D.Z., and R.H. have equity in Dialectic Therapeutics, which owns the license for DT2216.